骨髓生长因子药物利用评价标准的建立及应用

目的:建立骨髓生长因子药物利用评价标准(Drug Use Evaluation,DUE),并应用于分析骨髓生长因子临床使用的合理性。方法:采用"AGREEⅡ临床实践指南评估系统"筛选A级推荐的指南,根据A级推荐指南,构建骨髓生长因子DUE标准基本框架。结合新编药物学和药品说明书等,组织专家讨论并建立骨髓生长因子DUE标准。回顾性分析某三甲医院300例骨髓生长因子使用情况。结果:建立的骨髓生长因子评价标准主要包括用药适应证、用药方案、用药结果,血常规监测4个方面,应用结果显示某三甲医院使用骨髓生长因子的不合理现象主要表现为适应证、血常规监测、用药疗程、用法用量不合理。不合理率分别为20.67%,35.33%,28.33%,29.00%。结论:建立的骨髓生长因子DUE评价标准具有较好的应用性,实用性强,且易操作,可发现临床用药存在的问题和不足。

Establishment and application of drug use evaluation of myeloid growth factors

OBJECTIVE To establish drug use evaluation (DUE) of myeloid growth factors to analyze rationality of clinical use of myeloid growth factors. METHODS Appraisal of guidelines for research and evaluation II (AGREE II) instrument was used to screen guidelines on utilization of GSF with level A recommendation. Screened guidelines provided premise to build framework of DUE of myeloid growth factors. With instructions from new pharmacology and package insert of GSF, standards on DUE of myeloid growth factors were developed. Established DUE was used to conduct a retrospective study of 300 patients prescribed GSF in a 3A hospital. RESULTS DUE criteria on myeloid growth factors consisted of drug indications, results, medication regimens and routine blood test. Application results showed that irrational use rate of myeloid growth factors included indications, routine blood test, medical treatment, usage and dosage, and irrational rates were 20.67%, 35.33%, 28.33% and 29.00%, respectively.CONCLUSION DUE of myeloid growth factors established provides practicability and operabitity, and a reference for clinical rational use of GSF.